10 Best Non-Tech Stocks to Buy Now for Long Term

Page 5 of 10

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 98

Johnson & Johnson (NYSE:JNJ) researches and develops, manufactures, and sells various products in the healthcare field. In the fourth quarter of 2024, sales climbed 5.3% to $22.5 billion, driven by 6.7% operational growth and an adjusted operational growth of 5.7%. In February, the firm announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of a subcutaneous (under-the-skin) version of RYBREVANT. This version can be used with LAZCLUZE as a first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. It can also be used alone to treat adults with advanced NSCLC who have EGFR exon 20 insertion mutations and didn’t respond to platinum-based therapy.

Page 5 of 10